背景:一些调查报告显示,在体外受精-新鲜胚胎移植期间,与GnRH激动剂(GnRH-a)方案相比,使用促性腺激素释放激素拮抗剂(GnRH-ant)方案治疗的患者的着床率和临床妊娠率明显较低。随后的研究将这种不良结果归因于GnRH-ant对子宫内膜容受性的负面影响。然而,机制尚未完全了解。
方法:分析本中心2815例新鲜胚胎移植患者的临床资料。用GnRH类似物或伊马替尼(c-kit受体抑制剂)治疗来自健康女性的子宫内膜基质细胞(ESC),这些女性在妊娠8-10周时接受了正常妊娠的选择性妊娠终止。CCK8和流式细胞术用于研究ESCs的生长能力。免疫荧光染色和蛋白质印迹检测靶蛋白。
结果:临床资料显示GnRH-ant组HCG日子宫内膜厚度明显降低。虽然两组胚胎质量没有差异,GnRH-ant组HCG阳性率明显降低,胚胎植入和怀孕。此外,GnRH-ant显著降低ESCs的增殖并诱导其凋亡。此外,c-kit受体的表达和激活,在胚胎植入过程中发挥了关键作用,GnRH-ant明显减少。伊马替尼抑制c-kit的活化能显著抑制ESCs的增殖,促进ESCs的凋亡。此外,AKT的磷酸化和CyclinD1的表达与细胞生长密切相关,用伊马替尼治疗后明显减轻。
结论:总之,我们的研究表明,GnRH-ant通过降低c-kit受体的表达来削弱其活性,导致ESCs生长能力受损。我们的发现为GnRH-ant对子宫内膜的影响提供了新的见解。
BACKGROUND: Several surveys have reported that patients treated with gonadotropin-releasing hormone antagonist (GnRH-ant) protocol showed a significantly lower rate of implantation and clinical pregnancy compared to GnRH agonist (GnRH-a) protocol during in vitro fertilization-fresh embryo transfer. Subsequent studies imputed this poor outcome to the negative effects of GnRH-ant on endometrial receptive. However, the mechanisms were not fully understood.
METHODS: The clinical data of 2815 patients undergoing fresh embryo transfer in our center were analyzed. Human endometrial stromal cells (ESCs) from healthy women undergoing elective pregnancy termination of a normal pregnancy at 8-10 weeks gestation were treated with GnRH-analogs or imatinib (c-kit receptor inhibitor). CCK8 and Flow cytometry were used to investigated the growth ability of ESCs. Immunofluorescence staining and western blot was used to detected the target proteins.
RESULTS: The clinical data showed that the endometrial thickness on HCG Day were significantly lower in GnRH-ant group. Although no difference of embryo quality in these two groups, GnRH-ant group showed remarkably decreased rate of HCG positive, embryo implantation and pregnancy. Moreover, GnRH-ant significantly reduced the proliferation and induced the apoptosis of ESCs. Furthermore, the expression and activation of c-kit receptor, which played pivotal roles during embryo implantation, were observably decreased by GnRH-ant. Inhibiting the activation of c-kit by imatinib remarkably suppressed the proliferation and promoted the apoptosis of ESCs. Additionally, the phosphorylation of AKT and expression of Cyclin D1, which were closely related with cellular growth, were distinctly lessened after treating with imatinib.
CONCLUSIONS: In summary, our study showed that GnRH-ant weakened the activization of c-kit receptor by decreasing its expression, causing the impaired growth ability of ESCs. Our findings provided a new insight into the effects of GnRH-ant on endometrium.